Alzheimer's Disease Cooperative Study

Become a research participant today and make a difference for tomorrow! As such, the mandate of the ADCS is to:

1.

The Alzheimer's Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer's disease (AD) clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Division of Neurosci

ence's effort to facilitate the discovery, development and testing of new drugs for the treatment of AD. The ADCS was developed in response to a perceived need to advance research in the development of drugs that might be useful for treating patients with Alzheimer's disease (AD), particularly drugs that might not be developed by industry. Improve cognition, slow the rate of decline, or delay the appearance of AD.
2. Develop studies for promising agents designed to ameliorate behavioral symptoms.
3. Design new instruments for use in clinical studies.
4. Conceive of novel and innovative approaches to clinical study design and AD clinical study analysis.
5. Expand the range of patients studied in AD studies.
6. Enhance the recruitment of minority groups into AD studies. The ADCS focuses on evaluating compounds that will benefit the general good of AD patients. This includes the testing of agents that lack patent protection, are under patent protection but are already marketed for other indications but where the agent may be useful in treating AD, and are novel compounds developed by individuals, academic institutions and drug discovery units. Since 1991, the ADCS has initiated 30 research studies with the majority of studies carried out at 20 or more AD research centers. The number of participants enrolled in these Phase I to Phase III research studies have ranged from 9 to 800 people per study. ADCS studies have generated numerous publications. Some key highlights of ADCS activities include:

Development of AD centers capable of carrying out AD studies in the United States and Canada. Establishment of a robust Administrative, Data, Operations and Medical Cores based in San Diego. Development of important new instruments including the first Activities of Daily Living Scale specifically developed for AD patients, and standardization of the Clinical Global Impression of Change. Standardization and development of worksheets for the use of the Clinical Dementia Rating Scale. Completion of a protocol testing vitamin E and selegiline which demonstrated that both agents can cause approximately a six month delay in the time for moderately advanced AD patients to reach important endpoints including progression from moderate to severe dementia, loss of basic activities of daily living, institutionalization, and death. Development of the concept of mild cognitive impairment as a treatable entity and development of a clinical study to delay conversion from mild cognitive impairment to AD. Completion of a placebo-controlled, multi-center outpatient study of agitation in AD patients including two drug arms and one behavioral management arm. Completion of a number of studies with enormous scientific and public health impact, including studies demonstrating the lack of benefit associated with the use of estrogen, non-steroidal anti-inflammatory drugs, B vitamins and a statin drug for the treatment
of AD. Widespread sharing of assessment tools, trial methods and data with academic investigators and commercial entities around the world. Infrastructure support to other federally funded clinical efforts, including the Alzheimer's Disease Neuroimaging Initiative.

Decades of Work Leads to Clinical Trial for Early Alzheimer’s Treatment

12/21/2024

The BenfoTeam clinical trial testing thiamine/vitamin B1 is taking place at sites nationwide. Find a site near you at www.benfoteam.org

https://news.weill.cornell.edu/news/2024/12/decades-of-work-leads-to-clinical-trial-for-early-alzheimer%E2%80%99s-treatment

Decades of Work Leads to Clinical Trial for Early Alzheimer’s Treatment After years of research, Dr. Gary Gibson’s work has culminated in a nationwide clinical trial evaluating an entirely new treatment approach for slowing Alzheimer’s progression.

Empowered Patient Podcast: Raising Thiamine Levels in the Brain to Treat Early Alzheimer’s Disease Dr. Jose Luchsinger Benfo Team

12/06/2024

Raising Thiamine Levels in the Brain to Treat Early Alzheimer’s Disease, Dr. Jose Luchsinger on the Empowered Patient Podcast with Karen Jagoda. The BenfoTeam study is taking place at clinical sites across the country.

Empowered Patient Podcast: Raising Thiamine Levels in the Brain to Treat Early Alzheimer’s Disease Dr. Jose Luchsinger Benfo Team Dr. Jose Luchsinger, Vice Chair for Clinical and Epidemiologic Research at Columbia University, is leading a phase 2 clinical trial of a prodrug Benfo that aims to raise the level of thiamine in the brain to improve memory and function in people with early Alzheimer's disease. This effort is based o...

12/04/2024

How AI can help detect early warning signs of Alzheimer’s disease

11/22/2024

UC San Diego neurologist Dr. Gabriel Leger talks on The Today Show about early warning signs of Alzheimer's Disease.

How AI can help detect early warning signs of Alzheimer’s disease Doctors say that once Alzheimer’s takes over the brain there’s little they can do to stop it, but if you catch it early there are medication and lifestyle changes that can help slow it down. Now, new artificial intelligence technology could revolutionize Alzheimer’s detection and spot early wa...

Promising new Alzheimer’s treatment study now recruiting nationwide – Find out if you’re eligible

10/28/2024

BenfoTeam, a national clinical trial, has been launched to determine if benfotiamine (vitamin B1) works as a treatment for early Alzheimer’s disease. Find a clinical site near you.

Promising new Alzheimer’s treatment study now recruiting nationwide – Find out if you’re eligible If you're between 50 and 89 and suffer from mild AD, you could be eligible to take part.

Why is Alzheimer’s worse in women than men? UC San Diego researchers receive $5.2 million grant to find answers

07/04/2024

The Women Inflammation and Tau Study (WITS) at UCSD Shiley-Marcos Alzheimer's Disease Research Center uses brain imaging, thinking tests, biological fluid testing, and wearable technology to investigate potential biological and lifestyle factors that may contribute to Alzheimer’s-related brain changes in women. The study needs local participants. Watch this news story on KFMB Channel 8. To learn more about the study visit www.witsucsd.org or call (858) 761-3802. UC San Diego Shiley-Marcos Alzheimer's Disease Research Center at UC San Diego UC San Diego Women's Alzheimer's Studies

https://www.cbs8.com/article/news/local/alzheimers-worse-in-woman-than-men/509-8982d8f1-a467-445b-8418-f1b25a8dc151

Why is Alzheimer’s worse in women than men? UC San Diego researchers receive $5.2 million grant to find answers The “Women: Inflammation and Tau Study” is expanding and researchers are looking for more participants.

06/27/2024

The Women Inflammation and Tau Study (WITS) at Shiley-Marcos Alzheimer's Disease Research Center at UC San Diego uses brain imaging, thinking tests, biological fluid testing, and wearable technology to investigate potential biological and lifestyle factors that may contribute to Alzheimer’s-related brain changes in women. The study needs local participants. Watch this advance promotional trailer for a segment on the study that will air at 11 pm Thursday on KFMB Channel 8. To learn more about the study visit www.witsucsd.org

VIVA-MIND Alzheimer’s Disease Clinical Trial

03/12/2024

The VIVA-MIND clinical trial for people diagnosed with Mild Cognitive Impairment (MCI) and mild Alzheimer's disease is now taking place at medical sites across the country, including Georgetown University in Washington DC. Watch this explanatory video about the study. To talk to a prescreening specialist, call 844-234-7500

VIVA-MIND Alzheimer’s Disease Clinical Trial This is "VIVA-MIND Alzheimer’s Disease Clinical Trial" by Creative & Digital Strategy on Vimeo, the home for high quality videos and the people…

02/15/2024

The VIVA-MIND clinical trial for people with Mild Cognitive Impairment (MCI) and mild Alzheimer's disease is now taking place at medical sites across the country, including Barrow Neurological Institute in Phoenix. Watch this explanatory video about the study. To talk to a prescreening specialist, call 844-234-7500.

VIVA-MIND Alzheimer’s Disease Clinical Trial This is "VIVA-MIND Alzheimer’s Disease Clinical Trial" by Creative & Digital Strategy on Vimeo, the home for high quality videos and the people…

Photos from Alzheimer's Disease Cooperative Study's post

02/15/2024

VIVA-MIND is a clinical research trial at Oregon Health and Science University OHSU Brain Institute for people experiencing Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease. Call (503) 494-6370. Learn more: https://bit.ly/4bCnO5U

Alzheimer's Clinical Trial Looking For Participants

02/02/2024

The VIVA-MIND clinical trial at The Neuron Clinic in San Diego is evaluating whether an investigational oral drug is safe and can slow down or halt the progression of Alzheimer's disease. Call (844) 234-7500 to find out if you or a loved one qualify. The study is coordinated nationwide by UC San Diego. Watch principal investigator Dr. Jose Soria talk about the study on Fox5 San Diego. The Neuron Clinic can also conduct the study in Spanish.

Alzheimer's Clinical Trial Looking For Participants Dr. Jose Soria talks about a new Alzheimer's clinical trial looking for participants.

01/16/2024

Join us for this important lecture.

Want your school to be the top-listed School/college in La Jolla?

Click here to claim your Sponsored Listing.

Location

La Jolla

Contact the school

Click here to send a message to the school

Telephone

+18588226837

Website

http://www.adcs.org/

Address

9452 Medical Center Drive, 4th Floor
La Jolla, CA
92037